Elipse™, a Procedureless Gastric Balloon for Weight Loss: a Proof-of-Concept Pilot Study
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články
PubMed
26253980
DOI
10.1007/s11695-015-1783-7
PII: 10.1007/s11695-015-1783-7
Knihovny.cz E-zdroje
- Klíčová slova
- Gastric balloon, Intragastric balloon, Obesity, Overweight, Weight loss,
- MeSH
- dospělí MeSH
- hmotnostní úbytek fyziologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- nauzea etiologie MeSH
- obezita terapie MeSH
- pilotní projekty MeSH
- výsledek terapie MeSH
- žaludeční balónek škodlivé účinky MeSH
- zvracení etiologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Endoscopic gastric balloons have been used effectively as weight loss devices for decades, but the requirement for endoscopy and sedation poses several limitations. The goal of this pilot study was to evaluate the safety and performance of a prototype version of Elipse™, a procedureless gastric balloon. METHODS: Eight patients (mean BMI = 31.0 kg/m(2)) participated in this study. Each patient swallowed one Elipse™ balloon intended to remain in the stomach for 6 weeks, self-empty, and then pass. Each balloon was filled with 450 mL of filling fluid. Patients returned every 2 weeks for abdominal ultrasound. No specific diet or exercise plan was prescribed. RESULTS: All eight patients successfully swallowed the device. The most common adverse events were nausea and vomiting. There were no serious adverse events, and all balloons were excreted safely. Despite not being prescribed a diet or exercise plan, all eight patients lost weight. In 6/8 patients, the balloon remained full through 6 weeks, self-emptied, and passed. In one patient, the balloon appeared partially collapsed on ultrasound after 11 days and was endoscopically punctured. One asymptomatic patient elected to have the balloon endoscopically punctured after 19 days. Both balloons passed in the stool after 4 days. In both cases, endoscopic examination of the upper GI tract showed no abnormalities. CONCLUSIONS: This pilot study demonstrates the safety and performance of Elipse™, a procedureless gastric balloon for weight loss. Future studies will test a commercial design filled to 550 mL intended to last in the stomach for at least 12 weeks.
Allurion Technologies Wellesley MA USA
Department of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA
Faculty of Medicine University of Ostrava 17 Listopadu 1790 Ostrava 70800 Czech Republic
Internal Clinic Department of Gastroenterology University Hospital Ostrava Ostrava Czech Republic
Zobrazit více v PubMed
Obes Surg. 2001 Jun;11(3):330-3 PubMed
Obes Surg. 2008 Dec;18(12):1611-7 PubMed
Obes Surg. 2014 Jun;24(6):909-15 PubMed
Obes Surg. 2004 Apr;14(4):539-44 PubMed
Obesity (Silver Spring). 2015 Feb;23(2):277-81 PubMed
Int J Obes (Lond). 2006 Jan;30(1):129-33 PubMed
Obesity (Silver Spring). 2013 Aug;21(8):1561-70 PubMed
Int J Surg Case Rep. 2013;4(10):936-8 PubMed
Surg Endosc. 2011 Dec;25(12):3811-4 PubMed
Obes Surg. 2008 Jul;18(7):841-6 PubMed
Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):685-702 PubMed
Obes Surg. 2010 Nov;20(11):1496-500 PubMed
Obes Surg. 2013 May;23(5):730-3 PubMed
Obes Surg. 2013 Jul;23(7):953-8 PubMed
Gastrointest Endosc. 2015;81(6):1330-6 PubMed
Surg Obes Relat Dis. 2014 Mar-Apr;10(2):307-11 PubMed